Latest News and Press Releases

NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug...

Team Sanfilippo Foundation to Provide Funding for Planned FDA/EMA Open-Label Phase IIb/III and Expanded Access Study in Sanfilippo Syndrome Initial Patient Dosing is Scheduled to Begin in Q3 2019  ...

NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they have received a Notice of Allowance from...

NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has been added to the Russell Microcap®...

Validated, Pre-Clinical Success Shown in Modifying the Regulation of the SNCA Gene Which Encodes Alpha-Synuclein Expression Program Continues to Expand Seelos’ Alpha-Synuclein Targeted Parkinson’s...

─ Scheduled to Meet with FDA to Design Proof-of-Concept Study in Suicidality-PTSD ─ Appoints Warren W. Wasiewski, MD as Chief Scientific Officer ─ Seelos to Webcast Presentation at the Jefferies...

- First patient with Sanfilippo Syndrome expected to be dosed with Trehalose in an FDA/EMA open-label phase IIb/III trial in Q3 2019 – - Continuing progress to initiate phase I study with...

NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they will present and host 1x1 and small group...

- First patient with Sanfilippo Syndrome expected to be dosed with Trehalose in an open-label phase IIb trial in 2Q 2019 – - Plan to initiate phase I study with intranasal racemic ketamine in...

Well-Validated, Pre-Clinical Success Shown in the Reduction of Alpha-Synuclein New Compound Expands Seelos’ Parkinson's Portfolio NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics,...